Koenig Sheldon L.

Average Profitability
3.99%
Insider Buys Quantity
2
Insider Buys Sum
$75,142.08
Insider Sells Quantity
7
Insider Sells Sum
$145,696.80

Insider Activity of Koenig Sheldon L.

According to the SEC Form 4 filings, Koenig Sheldon L., being in a position of

  1. President and CEO at Esperion Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 26997 shares for $56,826,
    over all time since 2022-03-17, has bought 28606 shares for $75,142, and sold 47954 shares for $145,697.

The largest purchase of all time was on 2022-08-05 and amounted to 8606 shares of Esperion Therapeutics, Inc. for $49,950.

The largest sale of all time was on 2024-12-17 and amounted to 12447 shares of Esperion Therapeutics, Inc. for $30,694.

Biography of Koenig Sheldon L.

No biography is available at this moment.

2024-12-17SaleEsperion Therapeutics, Inc.
ESPR
President and CEO
12,447
0.0064%
$2.47$30,694-9.96%
2024-09-17SaleEsperion Therapeutics, Inc.
ESPR
President and CEO
14,550
0.0075%
$1.80$26,132+20.51%
2023-05-09PurchaseEsperion Therapeutics, Inc.
ESPR
President and CEO
20,000
0.0226%
$1.26$25,192+11.27%
2023-03-17SaleEsperion Therapeutics, Inc.
ESPR
President and CEO
6,999
0.0103%
$1.78$12,479-5.48%
2023-03-07SaleEsperion Therapeutics, Inc.
ESPR
President and CEO
5,441
0.0072%
$5.06$27,510-70.06%
2022-09-19SaleEsperion Therapeutics, Inc.
ESPR
President and CEO
3,394
0.0047%
$6.94$23,548-76.24%
2022-08-05PurchaseEsperion Therapeutics, Inc.
ESPR
President and CEO
8,606
0.0121%
$5.80$49,950-3.28%
2022-06-17SaleEsperion Therapeutics, Inc.
ESPR
President and CEO
4,552
0.0064%
$4.99$22,719+12.41%
2022-03-17SaleEsperion Therapeutics, Inc.
ESPR
President and CEO
571
0.0008%
$4.58$2,615+24.31%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.